Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | KLK7 | P49862 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formonetin SCHEMBL4728656 | 0.89 | RAB9A (0.83) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL10561558 | 0.88 | RAB9A (0.64) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL5272234 | 0.86 | PTPN1 (0.69) | RAB9AKLK7MAPTSMN1; SMN2KDM4E | |
| SCHEMBL12940987 | 0.85 | ALOX12 (0.59) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| Castanin SCHEMBL572274 | 0.85 | RAB9A (1.00) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL5273450 | 0.85 | ALOX12 (0.59) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL5275289 | 0.85 | ALDH1A1 (0.60) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL28495484 | 0.84 | RAB9A (0.65) | RAB9AKLK7MEN1KMT2AALDH1A1 | |
| SCHEMBL13904760 | 0.84 | MIF (0.64) | RAB9AKLK7KMT2AALDH1A1MAPT | |
| SCHEMBL29448332 | 0.82 | RAB9A (0.90) | RAB9AKLK7MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | RAB9A 1608/4885KLK7 1081/4885MEN1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.